Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from GlaxoSmithKline ( (GSK) ) is now available.
On 23 February 2026 GSK repurchased 462,000 ordinary shares at prices between 2,184p and 2,213p, at a volume‑weighted average of 2,200.95p, via BNP Paribas under its existing share buyback programme. The shares will be held in treasury, bringing total treasury holdings to 242,120,094 shares, while shares in issue excluding treasury stand at 4,074,032,332, which is also the updated total voting rights figure for regulatory disclosure purposes.
Since the non‑discretionary arrangement with the broker began on 17 February 2026, GSK has bought back 2,229,000 shares in aggregate, with the treasury position now representing 5.94% of voting rights in accordance with U.K. disclosure rules. The latest transactions underscore the company’s ongoing capital‑return strategy and slightly enhance earnings per share and ownership concentration for remaining shareholders by reducing the free float over time.
The most recent analyst rating on (GSK) stock is a Hold with a $70.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GSK Stock Forecast page.
Spark’s Take on GSK Stock
According to Spark, TipRanks’ AI Analyst, GSK is a Neutral.
The score is supported primarily by resilient fundamentals (strong profitability and positive cash generation) and a constructive earnings outlook with higher dividend guidance and continued specialty/HIV momentum. These positives are tempered by leverage and recent revenue/FCF volatility, while technically the stock is in a strong uptrend but looks overbought, raising near-term pullback risk.
To see Spark’s full report on GSK stock, click here.
More about GlaxoSmithKline
GSK plc is a global biopharmaceutical company headquartered in London, focused on the research, development and manufacture of prescription medicines and vaccines. The group targets major therapeutic areas such as infectious diseases, HIV, respiratory conditions and oncology, and its shares are listed in the U.K. with a broad international investor base.
Average Trading Volume: 4,852,035
Technical Sentiment Signal: Buy
Current Market Cap: $123B
See more data about GSK stock on TipRanks’ Stock Analysis page.